Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy—a role for early monitoring and intervention

Abstract excerpt

Poly ADP-ribose polymerase inhibitors (PARPi) are widely used as maintenance treatment for ovarian cancer (OC) after response to platinum chemotherapy in the first-line setting and recurrent disease. Their use has significantly improved outcomes, particularly in patients with BRCA mutations [ 1 ] in whom first-line PARPi maintenance therapy increases progression-free survival from 13.8 to 56.0 months (HR:0.33;...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to Chronic Lymphocytic Leukemia Research
• Share to PARP inhibition in cancer therapy